InterAx Biotech’s Post

#transcript Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid system, their lead drug candidate targets the major organs where CB1 receptors reside in fat tissue to increase mitochondrial activity and burn more fat.  #SkyeBioscience #Obesity #EndocannabinoidSystem #WeightLossDrug #CB1Receptor #GLP1 skyebioscience.com https://lnkd.in/gp3g2cZ3

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐆𝐏𝐂𝐑 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲! I would like to share some insights on G protein-coupled receptors (GPCRs) from a recent review by Zhang et al (STTT, 2024). Here are the key highlights: 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: Techniques like X-ray crystallography and cryo-EM have revolutionized our understanding of GPCR structures and dynamics. 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐃𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲: GPCRs play vital roles in sensory perception, neurotransmission, and endocrine regulation, with different subfamilies regulating various physiological functions. 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Understanding GPCR mutations linked to human diseases provides valuable insights for developing new therapeutic interventions. 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲: The review emphasizes the importance of detailed drug-target interactions in developing new drugs targeting GPCRs. Exciting times lie ahead in GPCR research and drug discovery! Follow me for more updates. #GPCRs #DrugDiscovery #BiomedicalResearch 🧬💊🔬

Newcells is revolutionising renal drug safety evaluation with cutting-edge kidney nephron models for safety studies. 👉 Key features of our Kidney Nephron Models: 1. aProximate™ Kidney Proximal Tubule Cells: 🔸Fully differentiated polarized cells 🔸Express relevant transporters for drug handling 🔸Allows the assessment of FDA-approved biomarkers for kidney toxicity Learn more about our kidney nephron models for renal safety profile assessment in vitro. Our platform is highly predictive of in vivo outcomes and our team of experts ensures reliable results. Discover more: https://lnkd.in/df_z9ZnR #Newcells #DrugSafety #Kidney #BiotechAdvancements #Innovation

Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy Article by Anil H. Kadam et al, using #Mediso nanoScan® SPECT/CT system. #imaging #preclinical #preclinicalresearch #molecularimaging #lungdisease

"#Prostaglandin, the metabolic product of arachidonates, regulates various physiologic functions through interacting and activating nine different prostaglandin receptors that belong to the G protein coupled receptor (#GPCR) family. Carboprost, an analog of prostaglandin F2α and an #Agonist for the prostaglandin F2-alpha #Receptor (FP receptor), is clinically used to treat #PostpartumHemorrhage (PPH). However, off-target activation of closely related receptors such as the prostaglandin E receptor subtype EP3 (EP3 receptor) by #Carboprost results in side effects and limits the clinical application. The most selective agonist for the FP receptor is #Latanoprost, which is a clinically used drug to treat elevated intraocular pressure in patients with #OcularHypertension or open-angle #Glaucoma, but is not suitable to treat PPH due to its poor solubility and fast #Clearance!" In this fantastic article published recently in Nature Portfolio Communications, researchers revealed the #CryoEM structures of the FP receptor in complex with carboprost and latanoprost: https://lnkd.in/edCXECjK These structures as well as the #Mutagenesis studies suggest the sub-pocket plays a key role in #Ligand #Selectivity. The high resolution structure information provided in this work will guide #DrugDevelopment and #DrugDesign of more selective #Drugs! #CryoEM #DrugDiscovery #Glaucoma #PPH

Hello everyone, I am very happy to tell that Physiogenex will be presenting two abstracts tomorrow June the 6th at #EASLcongress in Milan: 👉 Short timeline and no big budget to test your drug in a validated MASH mouse model? Stop by our poster THU-299 to learn about our fast and cost effective 4-week MASH mouse model, now validated with two essential benchmarks! 👉 25-30% of MASLD patients actually drink significant amount of alcohol, increasing the risk of liver cirrhosis. Want to check the effects of your drug on alcohol intake in a preclinical model? Come to the "Alcohol-related liver disease" oral abstract session at 5:15pm to discover our unique hamster models! Feel free to contact us to schedule a discussion about your next preclinical study with Physiogenex: https://lnkd.in/eR8rpD7H We have a 20-year experience in preclinical drug development and 97.5% customer satisfaction rate. Our expertise – your success. #EASL #liver #obesity #alcohol

Pulmonary Arterial Hypertension (PAH) is a rare, progressive condition marked by high blood pressure in the lungs' arteries. At ICE Bioscience, we're committed to supporting PAH drug discovery and development with cutting-edge models and assays: 🔺 In Vitro Models: Evaluating drugs like ACT-333679 for their potential to treat PAH using hypoxia-induced Rat PASMCs proliferation models. 🔺 Ex Vivo Assays: Studying the effects of medications such as Sildenafil through tension measurement of isolated rat pulmonary artery rings. 🔺 In Vivo Models: Exploring the effectiveness of drugs like Bosentan in improving PAH conditions using monocrotaline-induced rat models. #PAH #DrugDiscovery #PulmonaryArterialHypertension #PreclinicalResearch #ICEBioscience

At the 2024 ASCO Annual Meeting, we'll present data from the Phase 1 Study of our novel anti-CD137 antibody, CTX-471, and its safety and anti-tumor activity in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies. Clinical responses observed to date demonstrate the potential of our novel anti-CD137 antibody in patients with advanced refractory malignancies who have limited treatment options. Read more: https://ow.ly/QE7550RTQi4 With Thomas Schuetz. #CMPX #ASCO24 #biotech #biotechnology #healthcare #immunotherapy

𝗧𝗔𝗥𝗚𝗘𝗧𝗘𝗗 𝗗𝗥𝗨𝗚 𝗗𝗘𝗟𝗜𝗩𝗘𝗥𝗬 𝗜𝗡 𝗧𝗛𝗘 𝗚𝗔𝗦𝗧𝗥𝗢𝗜𝗡𝗧𝗘𝗦𝗧𝗜𝗡𝗔𝗟 𝗧𝗥𝗔𝗖𝗧 Join the 4th COLOTAN-ETN Symposium - January 10th, 2024 in Cork A great line up of speakers and topics to be expected: Gut feelings 2.0: Navigating Drug Absorption and Delivery in the 3D frontier Prof. Per Artursson Evaluation of the Enteric Delivery Performance of a Two-layer Functional Capsule Dr. Vincent Jannin Oral delivery of peptide drugs – impact of dosage form in preclinical studies Prof. Hanne Mørck Nielsen Drug delivery to the large intestine with xyloglucan-based tablets: In vitro, in vivo, in silico Prof. Georgios Imanidis Inflamed Gut Feelings: Story of Crohn Disease and Implications for Bioavailability and Bioequivalence Prof. Amin Rostami-Hodjegan Engineering functional nanocarriers for diagnosis and treatment of gastrointestinal diseases Associate Prof. Alexandra Teleki Gut Feelings: Targeting the Brain through the Gastrointestinal Tract Prof. John Cryan Do we really understand the colon for drug delivery? – A gastroenterologist view Prof. Subrata Ghosh See the full program and registration here: https://lnkd.in/e5-2fXpV #drugdelivery #gastrointestinal #excipients

🧬✨ Investigating the safety and effectiveness of a new drug combination for treating recurrent high-grade #Astrocytomas: A phase 1 clinical trial. 🧬✨ Astrocytoma is a type of brain tumor that originates from star-shaped glial cells in the brain called astrocytes. According to the WHO classification, they are classified into four grades based on the degree of malignancy and aggressiveness. Pilocytic astrocytoma and diffuse astrocytoma are considered low-grade astrocytomas, while anaplastic astrocytoma and glioblastoma multiforme are considered high-grade astrocytomas. High-grade astrocytomas are difficult to treat due to their aggressive nature and resistance to therapy. 🧠💊 This study contributes to the ongoing research on treatment options for malignant astrocytomas, specifically glioblastoma, and anaplastic astrocytoma. The combination of zotiraciclib with temozolomide, a standard chemotherapy drug, shows promising results regarding safety and tolerability. 💪❤️ For more details, watch our video @ https://lnkd.in/gcMyQzV7 and learn more about this groundbreaking trial and its potential to transform astrocytoma treatment. #CancerResearch #ClinicalTrials #BrainTumor #MedicalInnovation #Astrocytoma #Hope #Science #Medicine #Healthcare #Research #Breakthroughs #AstrocytomaSymptoms #AstrocytomaGrade2 #AstrocytomaGrade3 #AstrocytomaGrade4 #AstrocytomaPrognosis #AstrocytomaGrade1 #TypesOfAstrocytoma #AstrocytomaSymptoms #India #CellTalk #LifeScinces #Journal #HealthJournal #JournalClub #Healthcare #YouTube